Cencora Announces Leadership Succession Plan
2024年3月12日 - 9:30PM
ビジネスワイヤ(英語)
CEO Steven H. Collis to Transition to Executive
Chair; COO Robert P. Mauch to Become President and CEO
Both Appointments Effective October 1, 2024
Company Reaffirms Fiscal Year 2024 Guidance
Cencora, Inc. (NYSE: COR) today announced that Steven H. Collis
will retire as President and Chief Executive Officer of the Company
and transition to the role of Executive Chair of the Cencora Board
of Directors, effective October 1, 2024. Robert P. Mauch, PharmD,
PhD, current Chief Operating Officer of Cencora, will succeed
Collis as President and CEO, and will also be appointed as a member
of the Company's Board, effective the same date.
“Steve’s 30-year career at Cencora has been characterized by
purpose-driven leadership, delivering phenomenal growth in domestic
and international markets, diversification of the business, and the
successful launch of a global brand that positions the company for
even greater success. Since Steve’s appointment as CEO in 2011,
Cencora has delivered tremendous financial growth, with the
company’s annual revenue more than tripling to exceed $250
billion,” said Mark Durcan, Lead Independent Director of Cencora.
“Under his leadership, Cencora has grown into the global healthcare
leader it is today with its 46,000 team members spanning over 50
countries. Throughout his tenure, Steve has been a visionary
leader, forging the company’s leadership in specialty while
championing team member growth and development. On behalf of the
entire Board, I thank Steve for his considerable contributions to
our business, and look forward to continuing to benefit from his
deep industry knowledge and expertise as Executive Chairman,” said
Durcan.
“In my 30 years with Cencora, including 13 years as CEO, it has
been my privilege to lead our company as we have delivered robust
growth, made strategic investments and forged key partnerships. I
am particularly proud of the position we are in today where Cencora
is characterized by our strong industry leadership position,
intellectual confidence, and best-in-class talent and customer
relationships,” said Steven H. Collis, Chairman, President and
Chief Executive Officer of Cencora. “Together, the Cencora team has
built extraordinary relationships across our industry, expanded the
breadth of our innovative pharmaceutical solutions and grown our
global footprint, furthering our ability to advance our purpose of
creating healthier futures. Bob and I have worked closely for
nearly two decades, and I am proud that he will be the third CEO in
our company’s 23-year history. He has been an integral partner in
shaping and implementing our strategy and embodies our
purpose-driven culture. The company will benefit from his unique
background, expertise and proven leadership as he assumes the role
of CEO. I am excited to support Bob and the team as they continue
to advance our position at the center of healthcare.”
“Today’s announcement is consistent with the Board’s deliberate
and thoughtful approach to succession planning,” Durcan continued.
“Bob has experience across all aspects of our business and has
helped lead Cencora’s evolution to become a united, global provider
of pharmaceutical-centric healthcare solutions. The Board is
confident that he will continue to build on Cencora’s momentum to
drive value for our team, customers, partners and
shareholders.”
“I am honored to succeed Steve as President and CEO of Cencora
and am appreciative of his leadership and mentorship over the many
years we have worked together,” said Robert P. Mauch, EVP and Chief
Operating Officer of Cencora. “Throughout my years at Cencora, I
have been excited and motivated by our teams’ ability to adapt and
innovate to address the needs of our partners and I look forward to
continuing to drive our pharmaceutical-centric strategy forward,
supported by our talented team members and unwavering commitment to
our purpose.”
Today, Cencora is also reaffirming its fiscal 2024 guidance as
outlined on January 31, 2024.
About Robert P. Mauch
Bob Mauch is currently the Executive Vice President and Chief
Operating Officer of Cencora, Inc. In this role, he leads all of
Cencora’s domestic and international business units. Bob is focused
on building innovative solutions that advance the delivery of
pharmaceutical care, creating a best-in-class customer and partner
experience, and ensuring access to life-saving pharmaceutical care
for patients globally. Bob began his more than 30-year career in
pharmaceutical care as the founder of Xcenda (formerly Applied
Health Outcomes) which provides health economics as well as
strategic and reimbursement consulting to pharmaceutical companies.
Bob joined Cencora (formerly AmerisourceBergen) in 2007 when the
company acquired Xcenda. Since joining the company, Bob is credited
with leading the company’s transformation to a united, global
provider of pharmaceutical-centered healthcare solutions, driving
the company’s continued digital and commercial transformations,
developing and implementing an industry-shaping pricing strategy,
and implementing strategies to expand operations globally. Bob
received his Pharm.D. from Mercer University and his Ph.D. in
pharmaceutical science from the University of South Carolina where
he pursued a focus in health economics and outcomes research.
About Cencora
Cencora is a leading global pharmaceutical solutions
organization centered on improving the lives of people and animals
around the world. We partner with pharmaceutical innovators across
the value chain to facilitate and optimize market access to
therapies. Care providers depend on us for the secure, reliable
delivery of pharmaceuticals, healthcare products, and solutions.
Our 46,000+ worldwide team members contribute to positive health
outcomes through the power of our purpose: We are united in our
responsibility to create healthier futures. Cencora is ranked #11
on the Fortune 500 and #24 on the Global Fortune 500 with more than
$250 billion in annual revenue. Learn more at
investor.cencora.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240311064389/en/
Investors: Bennett S. Murphy Senior Vice President,
Head of Investor Relations & Treasury 610-727-3693
Bennett.Murphy@cencora.com
Media: Mike Iorfino 610-545-9189
Mike.Iorfino@cencora.com
Cencora (NYSE:COR)
過去 株価チャート
から 4 2024 まで 5 2024
Cencora (NYSE:COR)
過去 株価チャート
から 5 2023 まで 5 2024